Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Capital Expenditures (2017)

Tenax Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at $1.0 for Q4 2017.

  • For Q4 2017, Capital Expenditures changed N/A year-over-year to $1.0; the TTM value through Dec 2017 reached $4537.0, up 57.32%, while the annual FY2022 figure was $2323.0, 55.77% down from the prior year.
  • Capital Expenditures for Q4 2017 was $1.0 at Tenax Therapeutics, down from $1264.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 million in Q1 2014 and bottomed at $1.0 in Q4 2017.
  • The 4-year median for Capital Expenditures is $3272.0 (2017), against an average of $259584.1.
  • The largest annual shift saw Capital Expenditures plummeted 99.76% in 2015 before it increased 13.45% in 2017.
  • A 4-year view of Capital Expenditures shows it stood at $1.8 million in 2014, then crashed by 99.07% to $16688.0 in 2015, then tumbled by 82.72% to $2884.0 in 2016, then crashed by 99.97% to $1.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Capital Expenditures are $1.0 (Q4 2017), $1264.0 (Q3 2017), and $3272.0 (Q1 2017).